Skip to content
Clinical Trials – home

IRCCS Istituto Giannina Gaslini

Research site

Italy Via Gerolamo Gaslini 5, 16147 Genoa, Italy

  • 99 trials recruiting
  • Cystic fibrosis · Juvenile idiopathic arthritis · Acute lymphocytic leukaemia
  • Adults and children

About Specializations

IRCCS Istituto Giannina Gaslini in Genoa, Italy specialises in clinical trials of conditions such as Cystic fibrosis, Juvenile idiopathic arthritis, Acute lymphocytic leukaemia, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Pediatric Rheumatology and Immune-Mediated Diseases

The IRCCS Istituto Giannina Gaslini in Genoa is actively studying juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, lupus nephritis, Behçet’s disease, and other inflammatory conditions. This research focuses on improving symptom control, guiding treatment decisions, and finding safer long-term ways to manage chronic immune-related disease in children and adolescents.

  • Juvenile idiopathic arthritis and treatment withdrawal strategies
  • Lupus nephritis and related autoimmune kidney disease
  • Behçet’s disease, Still’s disease, and other systemic inflammatory disorders

These studies aim to refine care by testing whether personalized approaches can better balance disease control and treatment burden.

Pediatric Oncology and Hematologic Malignancies

Major research at this site centers on pediatric cancers, especially acute lymphoblastic leukemia, lymphoblastic lymphoma, neuroblastoma, medulloblastoma, glioma, and acute myeloid leukemia. The studies explore new cancer treatments, molecularly targeted therapies, and better strategies for children whose disease has returned or not responded to standard care.

  • Relapsed or refractory leukemia and lymphoma
  • High-risk neuroblastoma and other solid tumors
  • Brain tumors such as medulloblastoma, ependymoma, and diffuse intrinsic pontine glioma

The overall goal is to improve survival, reduce relapse, and match treatments more closely to each child’s tumor biology.

Kidney Disease, Transplantation, and Proteinuric Disorders

Clinical trials at IRCCS Istituto Giannina Gaslini also address a broad range of kidney diseases, including chronic kidney disease, proteinuria, nephrotic syndrome, IgA nephropathy, Alport syndrome, and post-transplant complications. This work is designed to improve kidney protection, reduce protein loss in urine, and support better outcomes after transplant.

  • Chronic kidney disease with proteinuria in children
  • Nephrotic syndrome and other glomerular diseases
  • Adolescent renal transplant care and immunosuppression management

Research in this area is largely aimed at evaluating treatments that may preserve kidney function and improve long-term disease control.

Neurology, Epilepsy, and Neurodevelopmental Disorders

The site has strong activity in neurological disorders such as Dravet syndrome, Lennox-Gastaut syndrome, developmental and epileptic encephalopathies, spinal muscular atrophy, Duchenne muscular dystrophy, and Rett syndrome. These trials are focused on testing new therapies, improving seizure control, and understanding how treatments affect function and daily life.

  • Epilepsy and severe seizure syndromes
  • Neuromuscular diseases such as spinal muscular atrophy and Duchenne muscular dystrophy
  • Neurodevelopmental disorders including Rett syndrome and CDKL5 deficiency disorder

These studies aim to improve both symptom management and longer-term neurological outcomes in children.

Respiratory, Cystic Fibrosis, and Asthma Research

Respiratory research at the site includes cystic fibrosis, severe asthma, bronchiectasis, and chronic lung disease. The trials are examining new therapies and better ways to maintain lung function, reduce flare-ups, and support children with chronic breathing problems.

  • Cystic fibrosis and long-term respiratory care
  • Severe uncontrolled asthma in children
  • Chronic lung disease in premature infants and other pediatric patients

This work is aimed at improving everyday respiratory health and lowering the burden of long-term lung disease.

Endocrinology, Growth, and Metabolic Disorders

Within the U.O.C. Clinica Pediatrica-Endocrinologia, the research portfolio includes growth hormone deficiency, Prader-Willi syndrome, classic congenital adrenal hyperplasia, Glycogen Storage Disease Type Ia, Wilson disease, and other metabolic disorders. These studies are designed to evaluate new treatments, improve disease control, and address complications that affect growth, appetite, and metabolism.

  • Growth and endocrine disorders in children
  • Prader-Willi syndrome and appetite-related symptoms
  • Inherited metabolic diseases including Wilson disease and glycogen storage disorders

The research aims to support more effective, child-friendly approaches for long-term endocrine and metabolic care.

Cardiovascular, Hematology, and Rare Blood Disorders

Clinical trials here also cover heart failure, hemophilia, sickle cell disease, thrombocytopenia, and other hematologic disorders. The focus is on improving disease stability, preventing bleeding or vaso-occlusive events, and testing treatments that may offer better control of chronic blood-related conditions.

  • Hemophilia and bleeding disorders
  • Sickle cell disease and crisis prevention
  • Heart failure and related pediatric cardiovascular care

These studies are intended to strengthen supportive care and evaluate therapies that may improve safety and quality of life.

Immunology, Transplant Complications, and Inflammatory Conditions

Research at the site includes immune system diseases such as chronic graft-versus-host disease, hemophagocytic syndromes, post-transplant viral reactivation, and immune-mediated inflammatory disorders. The studies seek to improve treatment effectiveness, reduce complications after transplant, and better control severe immune activation.

  • Post-transplant complications after hematopoietic stem cell transplant
  • Chronic inflammatory immune disorders
  • Viral reactivation and transplant-related immune dysfunction

This line of research reflects a strong interest in safer, more targeted management of complex pediatric immune conditions.

Surgical, Diagnostic, and Perioperative Research

The site also contributes to studies in diagnostic techniques, therapeutics, and surgical procedures, including research on anesthesia and outcomes around planned operations in young children. These trials are aimed at improving safety, refining care pathways, and supporting better recovery after procedures.

  • Anesthesia and perioperative care in young children
  • Diagnostic and therapeutic techniques for pediatric care
  • Surgical outcomes and recovery support

Work in this area complements the broader pediatric research program by improving how care is delivered across different clinical settings.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Gerolamo Gaslini 516147 GenoaItaly
Recruiting now
99 trials
Conditions studied
118

More sites in GenoaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

180 clinical trials

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:Avidity Biosciences Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

BMN 333 Versus Vosoritide in Children With Achondroplasia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Vosoritide
  • Sponsor:Biomarin Pharmaceutical Inc.

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Clemizole Hydrochloride
  • Sponsor:Epygenix Therapeutics Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anumigilimab
  • Sponsor:CSL Behring LLC
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.